Literature DB >> 9486579

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

Y Shimizu1, S Kamoi, S Amada, F Akiyama, S G Silverberg.   

Abstract

BACKGROUND: Most published series of ovarian carcinoma find a correlation between histologic grade and survival, but the grading system used commonly is not specified, and several different systems exist, some of which use different criteria for different histologic types. However, several studies have shown marked interobserver variability in distinguishing among the histologic types of ovarian carcinoma. The authors attempted to derive a universal grading system for all invasive ovarian carcinomas (IOC), based on the Nottingham system for grading all types of mammary carcinoma.
METHODS: The authors studied 461 patients with IOC of different histologic types and clinicopathologic stages who were treated in a uniform manner between 1980 and 1994 with surgery and cisplatin-based chemotherapy. All slides were reviewed and the tumors graded as follows: Architectural pattern (predominant): Glandular = 1, Papillary = 2, and Solid = 3; Nuclear pleomorphism: Slight = 1, Moderate = 2, and Marked = 3; Mitotic activity (mitotic figures per 10 high-power fields [1 HPF = 0.345 mm2]) in most active region: 0-9 = 1, 10-24 = 2, and > or = 25 = 3; Grade 1 = total score (adding three values obtained earlier) 3-5, Grade 2 = 6 or 7, and Grade 3 = 8 or 9.
RESULTS: Tumor grade correlated with survival in both early and advanced stage disease and for all major histologic types of IOC except clear cell carcinoma (CCC). Results for CCC approached but did not reach clinical significance. By multivariate analysis, only this tumor grade and performance status were significant in Stage I/II IOC. For Stage III/IV tumors, the new tumor grade also was significant, as were performance status, residual tumor size, response to chemotherapy, and mucinous (unfavorable) or transitional cell (favorable) histologic type. International Federation of Gynecology and Obstetrics grade (based primarily on architectural features) did not correlate significantly with survival except in Stage III/IV serous and Stage I/II mucinous carcinomas.
CONCLUSIONS: The new grading system reported is simple, reproducible (among the current study authors), and useful for all histologic types and clinical stages of IOC. Further testing for reproducibility and clinical utility is recommended.

Entities:  

Mesh:

Year:  1998        PMID: 9486579     DOI: 10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  54 in total

1.  Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

Authors:  Paweł Surowiak; Verena Materna; Irina Kaplenko; Marek Spaczyński; Manfred Dietel; Hermann Lage; Maciej Zabel
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 3.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 4.  [Histological grading of epithelial ovarian cancer. Review and recommendation].

Authors:  S Hauptmann; A du Bois; I Meinhold-Herlein; J Pfisterer; S Avril
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

5.  Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Authors:  Mika Fujiwara; Valerie A McGuire; Anna Felberg; Weiva Sieh; Alice S Whittemore; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

6.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Authors:  Stefan Kommoss; Dietmar Schmidt; Friedrich Kommoss; Juergen Hedderich; Philipp Harter; Jacobus Pfisterer; Andreas du Bois
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

7.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

8.  Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.

Authors:  Samir F Zohny; Salah T Fayed
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

9.  Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.

Authors:  Nassima Redjimi; Françoise Gaudin; Cyril Touboul; Dominique Emilie; Marc Pallardy; Armelle Biola-Vidamment; Hervé Fernandez; Sophie Prévot; Karl Balabanian; Véronique Machelon
Journal:  Mol Cancer       Date:  2009-10-08       Impact factor: 27.401

10.  Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.

Authors:  Yun-Hyun Cho; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Kyu-Rae Kim; Joo-Hyun Nam; Young-Tak Kim
Journal:  Yonsei Med J       Date:  2009-04-30       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.